Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-nephropathy study of tofogliflozin in type 2 diabetes with diabetic nephropathy
jRCTs031190185Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofogliflozin in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis, sponsored by Kowa Company, Ltd. Primary endpoint: Change in urinary albumin-to-creatinine ratio from baseline to week 60. Started Jan 2020; status: completed.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs031190185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190185.